CAR-T Increases Overall Survival in Relapsed/Refractory LBCL.

Published Date: 10 Jun 2023

Axicabtagene ciloleucel, a CAR T-cell therapy drug, significantly increased overall survival compared to conventional second-line therapies in patients with early relapsed or refractory large B-cell lymphoma.

Read Full News

Latest News



Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

An ancient signaling pathway and 20 years of research offer hope for rare cancer

2.

Off-the-Shelf Drug Matches CAR-T Effects in Refractory Lupus

3.

Brigatinib Makes Its Case for ALK-Positive ALCL in Small Study

4.

I Understand Why Defense Secretary Austin Kept His Prostate Cancer Quiet.

5.

Prostate cancer detection with PET CT and PET MRI is comparable.


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot